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Natural history studies of tuberculosis (TB) have revealed a spectrum of clinical outcomes
after exposure to Mycobacterium tuberculosis, the cause of TB. Not all individuals
exposed to the bacteriumwill become diseased and depending on the infection pressure,
many will remain infection-free. Intriguingly, complete resistance to infection is observed
in some individuals (termed resisters) after intense, continuingM. tuberculosis exposure.
After successful infection, the majority of individuals will develop latent TB infection
(LTBI). This infection state is currently (and perhaps imperfectly) defined by the presence
of a positive tuberculin skin test (TST) and/or interferon gamma release assay (IGRA),
but no detectable clinical disease symptoms. The majority of healthy individuals with
LTBI are resistant to clinical TB, indicating that infection is remarkably well-contained in
these non-progressors. The remaining 5–15% of LTBI positive individuals will progress to
active TB. Epidemiological investigations have indicated that the host genetic component
contributes to these infection and disease phenotypes, influencing both susceptibility and
resistance. Elucidating these genetic correlates is therefore a priority as it may translate
to new interventions to prevent, diagnose or treat TB. The most successful approaches
in resistance/susceptibility investigation have focused on specific infection and disease
phenotypes and the resister phenotype may hold the key to the discovery of actionable
genetic variants in TB infection and disease. This review will not only discuss lessons
from epidemiological studies, but will also focus on the contribution of epidemiology and
functional genetics to human genetic resistance toM. tuberculosis infection and disease.
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INTRODUCTION
Tuberculosis (TB), caused by the human pathogen Mycobacterium tuberculosis, was the leading
cause of death due to a single infectious agent in 2016, resulting in 1.6 million deaths (1). The
bacterium is spread through the air by droplet nuclei containing M. tuberculosis from the lungs
of individuals with active disease to the respiratory tract of uninfected individuals (2). Infection
by M. tuberculosis is a complex, multistage process progressing from the first encounter with
the bacterium (Figure 1). For this reason a multistep course of disease has to be imagined (5).
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FIGURE 1 | A simplified representation of the Mycobacterium tuberculosis infection spectrum and outcomes. The bacteria enter the respiratory system of the host via
inhaled droplets and are engulfed by macrophages and dendritic cells. There are four potential outcomes after bacterial inhalation: (i) M. tuberculosis is immediately
eliminated by the pulmonary immune system, (ii) the bacteria are contained in granulomas by recruited adaptive immune cells (including T cells and B cells) and
infection does not progress to active TB. Although this containment can last for a lifetime, M. tuberculosis can also disseminate from granulomas (reactivation) or
reinfection with another mycobacterial strain can occur, resulting in active TB, (iii) sub-clinical disease characterized by intermittent symptoms and periodic
infectiousness, or (iv) infection develops into active TB. Adapted from Pai et al. (3) and Möller et al. (4).
After inhalation, the droplet nuclei move to the alveoli where the
bacteria are phagocytosed by alveolar macrophages and dendritic
cells. The phagocytosis of the bacterium invokes a strong host
cellular immune response and a cascade of events is triggered
that involves cytokines and chemokines (2). Not all individuals
exposed to the bacterium will become infected and depending
on the infection pressure, many will remain free of infection.
In infected individuals the bacteria will begin to replicate in the
intracellular environment and migrate to lymph nodes in the
lung through the lymphatic system (6). In the first 2–8 weeks
after infection, cell-mediated immunity will develop (7) and
conversion to tuberculin reactivity takes place (6). To limit the
spread and replication of the bacteria, granulomas are formed
by activated T lymphocytes and macrophages. The majority of
individuals will remain asymptomatic and contain the bacterium,
and enter a stage termed latent TB infection (LTBI). Remarkably,
it is estimated that ∼25% of the global population was latently
infected with M. tuberculosis in 2014 (8). At this stage the
immune system can contain the infection, but if it fails, the
infection may progress to active disease (7). Only 5-15% of
immunocompetent LTBI positive individuals will progress to
clinical TB (8). In these cases, the bacteria continue to replicate
and disease symptoms will start to appear. Common symptoms
of TB include persistent coughing, fever, coughing of blood, night
sweats, weight loss, and chest pain. Diagnosis of pulmonary TB is
possible through smear microscopy, bacterial culture of sputum
or GeneXpert (9).
LTBI is at present inferred from measures of acquired
anti-mycobacterial immunity, such as a tuberculin skin test
(TST) and/or interferon gamma release assay (IGRA). The
TST was the original gold standard for LTBI diagnosis
(10). A delayed hypersensitivity reaction to mycobacterial
antigens is measured by injecting tuberculin purified protein
derivative (PPD) intradermally into the forearm, followed by
measuring the induration 48 h later (10). A positive TST in
an immunocompetent individual is defined as an induration
of 10 or more millimeters in high prevalence countries. The
PPD antigens are not specific to M. tuberculosis and may result
in false positive reactions if individuals were exposed to non-
tuberculous mycobacteria or immunized withM. bovis BCG (10).
In contrast, IGRA is a whole blood assay, which uses the specific
M. tuberculosis antigens ESAT-6, CFP-10, & TB7.7 to stimulate
antigen-specific CD4T cells to release interferon gamma, which
is then measured. Even within LTBI individuals there is a
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spectrum of infection states ranging from the early elimination
of infection to subclinical TB, which cannot be differentiated by
TST or IGRA (11–16).
In the case of immediate bacterial clearance, or complete
resistance to infection (observed in a small fraction of the
population) the innate immune system will inactivate the
bacteria at the site of infection without the stimulation of an
acquired immune response. These individuals, recently labeled
innate resisters by Simmons et al. will have continued negative
TST or IGRA results despite heavy and continued exposure
to M. tuberculosis and will not be at risk of clinical TB
(11, 17). The resister phenotype is likely heterogeneous and could
include individuals who mount a protective adaptive immune
response (termed adaptive resisters) perhaps involving B cells
or unconventional T cell responses during early clearance of
the bacterium (17). Also of interest are those LTBI individuals
who have no risk of progression to clinical TB, labeled non-
progressors, possibly due to an exceptionally well-contained
infection or absence of viable bacteria in the granuloma (18).
The elucidation of the genetic correlates that contribute to these
infection and disease resistance phenotypes is a priority as it may
translate to new interventions to prevent, diagnose, or treat TB.
Genetic investigations of TB susceptibility have been ongoing
for decades, but gained momentum in recent years due to
the availability of improved methodological approaches and
technological advances. The majority of studies made use
of classical approaches employed by clinical genetics and
genetic epidemiology (linkage and association studies), but
these have encountered difficulties also faced by genetic
investigations of other complex diseases. Three continuing
challenges involve polygenicity, the definition of TB phenotypes
and the collection of appropriately large study cohorts with
carefully defined homogenous phenotypes (11, 19, 20). More
recently functional genetic studies, including epigenetics,
microRNAs and transcriptomics, have also shed light on the
genetic basis of TB susceptibility (21). This review will discuss
the early epidemiological evidence of genetic susceptibility to
M. tuberculosis infection and disease progression, but will also
focus on the contribution of genetic epidemiology and functional
genetics while highlighting controversies, current research gaps,
and future developments.
EPIDEMIOLOGICAL EVIDENCE OF
GENETIC SUSCEPTIBILITY TO M.
TUBERCULOSIS INFECTION AND
CLINICAL TB RESISTANCE
Epidemiological evidence confirms the presence of both resisters
and non-progressor phenotypes in high exposure settings.
Approximately 50% of close household contacts develop positive
TST or IGRA tests (22–26) and there are multiple examples
of homogenous high exposure and heterogeneous infection
[reviewed by Verrall et al. (27)]. For example the HIV epidemic
resulted in TB control failure in South African mines during
the 1990s with notification results exceeding 4,000 per 100 000
person-year (28). In the midst of this perfect TB storm, 13%
of HIV negative miners had TST = 0mm responses (28). TB
outbreaks onboard ships of the United States Navy yielded
similar findings with 5–10% of crew members at highest risk
of exposure remaining TST negative (29, 30). Likely resisters
were also detected amongst nurses who were exposed to TB
patients (31–34). The contribution of hereditary factors to
clinical disease susceptibility was recognized even before the
discovery of the bacterium, due to the observation that TB
often occurred in several individuals from the same family
(35). Koch’s discovery of the bacterium in 1882 meant that it
would be several decades before the host genetic component
would again be considered as a contributing factor to disease.
In 1943 a seminal study investigating TB concordance found
that monozygous twins were significantly more likely to both
become diseased than dizygous twins (66.7 vs. 23%) (36). The
study also included relatives of the twins and found that the
degree of relatedness to the TB index case determined the risk
of developing active disease (36). Descriptions of the natural
history of clinical TB from the era before antibiotic treatment
provide valuable insights into resistance to active disease. For
example, pulmonary TB in immunocompetent individuals with
no antimicrobial chemotherapy was fatal in ∼50% of cases; 25%
of individuals remained ill with chronic TB and the remaining
25% spontaneously achieved cure (37).
In addition to these “experiments of nature,” animal models
have provided important evidence for a contribution of host
genetics to TB infection and progression to clinical disease.
Different patterns of disease resistance after infection have been
observed in guinea pigs and inbred strains of mice (38). The
rabbit model was extensively used by Lurie et al. to study
resistance to disease progression and clearly represented two
forms of genetically controlled resistance (39–41). The so-
called “resistant” rabbits survived approximately twice as long as
susceptible rabbits. Susceptible rabbits developed disseminated
disease, while resistant rabbits developed cavitary TB (40, 42).
An additional evaluation of Lurie’s findings by Werneck-Barroso
indicated that 20–40% of rabbits exposed to the bacterium did
not develop disease and the majority of these did not become
TST positive, even after prolonged exposure (43). This suggests
that some animals had an intrinsic ability to resist natural
M. tuberculosis infection and that the bacteria were eliminated
without stimulating an acquired immune response (43).
No review of TB susceptibility would be complete without a
discussion of the Lübeck disaster. During this tragedy, which took
place from December 1929, 251 infants over a time period of
4 months were vaccinated with BCG accidentally contaminated
with varying amounts of virulent M. tuberculosis [reviewed
by Fox et al. (44)]. Clinical or radiological signs of TB were
observed in 173 survivors, but 72 infants died from TB (44).
Fox et al. pointed out three key lessons resulting from the
accident. Firstly, 156 (68%) of those who had developed clinical
disease, spontaneously resolved their symptoms, suggesting that
newborn infants are remarkably resistant to TB. Secondly, based
on available data, semiquantitative levels of M. tuberculosis
contamination were inferred. At low levels of contamination,
a wide range of clinical phenotypes was seen, revealing the
extent of innate resistance to clinical TB. However, at high
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doses of M. tuberculosis contamination, most babies were
susceptible to disease, indicating that extreme exposure will
eventually overcome host innate (genetic) resistance to disease
(44). Therefore, the dose of M. tuberculosis is key to determine
TB outcome. Lastly, two infants received vaccines with the lowest
levels of contamination, but quickly progressed to disease and
death, perhaps indicating that they were most susceptible to
TB (44).
Isolated populations with little or no known past exposure
to the TB bacterium, such as the indigenous populations of
the Americas and sub-Saharan Africa, have a significantly
higher TB mortality than non-indigenous populations whose
ancestors had a longer mycobacterial exposure time (45–47).
These observations support the “virgin soil” hypothesis, which
postulates that the previous lack of exposure to a pathogen leads
to hyper-susceptibility to infection, morbidity and mortality.
Newer DNA evidence indicates that theM. tuberculosis complex
was in fact already widespread around 4000 years ago in Ethiopia
and TB infection was also found in western-central and western
African individuals who arrived in Brazil as slaves during
1769–1830 (48, 49). The introduction of (European) TB strains
possibly exacerbated by local host genetic factors and poor living
conditions, contributed to the high mortality observed in these
“naïve” populations (50). For example, analyses of the indigenous
population of Canada, limited to the Qu’Appelle Agency located
in Southeastern Saskatchewan, indicated an annual TB mortality
rate of 10% in 1890 which fell to 0.2% after 40 years, but
half of the population was eradicated (45). This is suggestive
of a strong selection for TB resistance genes. More recent
examples of the introduction ofM. tuberculosis to underexposed
populations is that of the Northern Aché of eastern Paraguay
and the Yanomami Indians of the Brazilian Amazon (47, 51).
Prevalence (18.2%) and infection (64.6%) rates in the Northern
Aché quickly rose within 6 years of the first detected TB case (51).
TST anergy, possibly reflecting reduced cell-mediated immune
responses, and increased antibody responses were common in
individuals with active TB from both these populations (47, 51).
This could indicate that there has been no selection for TB
resistance mechanisms in these groups. In contrast, the decline
in TB incidence in North America and Europe during 1830–950,
before the introduction of antimicrobial chemotherapy, has been
ascribed to the increase of genetically determined resistance to
TB due to natural selection after years of mycobacterial exposure
(35, 48, 52–55). However, an estimation using Swedish fertility
and mortality data, which included age-specific pulmonary
TB mortality, from 1891 to 1900 indicated that changes in
only the genetic make-up of the population would have been
unlikely to account for the extreme decline in TB mortality
(56). Although surviving individuals had a fitness advantage
of 7–15% per generation compared to individuals who died,
statistical calculations indicated that selection would only have
reduced the frequency of rare susceptibility variants if these
variants had large effects. In contrast, if rare resistance variants
were in fact rare, 300 years would not have been sufficient
for selection to increase the frequency of these variants to
epidemiologically significant frequencies. Despite this, evidence
for the role of natural selection in TB resistance is bolstered by
findings from population genetic studies of the immune system
which provide a context for the genetic interface between humans
and mycobacteria (57–61).
HERITABILITY, GENETIC EPIDEMIOLOGY,
AND POPULATION GENETICS
Heritability, genetic epidemiology, and population genetic
studies have made significant contributions to reveal the role
of human genetic variation in susceptibility to TB infection.
The investigations of TST and IGRA as quantitative traits have
shown high heritability for both, conditional to M. tuberculosis
exposure (TST above 50% and for IGRA between 30 and 50%).
Heritability of quantitative TST reactivity (in mm) among young
healthy children exposed to an active TB case was estimated
at 92% in Chile (62). In the Gambia, the heritability of TST
considered as a categorical trait and quantitative IGRA reactivity
in healthy twins aged 12 to 83 years was estimated at 71 and
39%, respectively (63). In Colombia evidence was detected for
a major co-dominant gene explaining ∼65% of TST variability
(64), and in a South African familial sample, the heritability of
quantitative IGRA responses was estimated to be between 43
and 58%, depending on the nature of the stimulating antigen
(65). Recent data from Uganda, carefully adjusted for shared
environment, also detected significant heritability of interferon
gamma in response to M. tuberculosis culture filtrate (23–35%),
ESAT6 (15–48%), and Antigen 85B (11–34%) (66).
Only a few molecular studies have investigated the genetic
factors underlyingM. tuberculosis infection resistance using TST
reactivity. Candidate gene association studies have focused on
TST response as a binary trait according to various thresholds
(0, 5, or 10mm) with a weak association reported for interleukin
10 (IL10) promoter variants (67, 68). Increased IL-10 production
may contribute to the suppression of adaptive immune responses
(68). A candidate gene association study of autophagy-related
genes and LTBI, defined by a TST response greater than 5mm,
identified an association between a non-coding Unc-51 Like
Autophagy Activating Kinase 1 gene (ULK1) variant and LTBI
(69). A possibly associated role for ULK1 in the regulation of
TNF secretion, both non-specific and M. tuberculosis–induced
autophagy, and M. tuberculosis replication in monocytes was
established (69). A genome-wide association study (GWAS) of
TST reactivity in HIV positive individuals from Tanzania and
Uganda pinpointed a polymorphism on chromosome 5q31.1
that protected against M. tuberculosis infection (Table 1) (80).
This variant is located near the gene encoding IL-9, which is
produced by mast and Th2 cells during inflammatory responses
and has been associated with bronchial responsiveness, possibly
linking resistance against M. tuberculosis infection and airway
inflammation (80). A GWAS in Iceland detected associations
between TST positivity (induration size not specified) and HLA
class II variants (Table 1) (79). An imputed GWAS was done
in 4,426 cases with a self-reported positive TST (defined as
the presence of an induration) and 84 290 controls selected
from more than 200 000 23andMe participants with European
ancestry who completed a questionnaire on infection history
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TABLE 1 | GWAS of TB infection and disease phenotypes. Adapted from Kinnear et al.(20).
Population Phenotype Cases Controls Variant Gene Odds ratio
[95% CI]
Reference
Ghana TB 921 1740 rs4331426 Gene desert
(chromosome 18)
1.19 [1.13–1.27] (70)
Gambia – 1316 1382 – – – –
USA Extrapulmonary TB 48 57 rs4893980 PDE11A 0.13 (71)
– – – – rs10488286 KCND2 11.15 –
– – – – rs2026414 PCDH15 3.11 –
– – – – rs10487416 Unknown gene 5.56 –
Thailand Young TB 433 295 rs6071980 HSPEP1, MAFB (intergenic,
chromosome 20q12)
1.73 [1.42–2.11] (72)
Japan – 188 934 – – – –
Indonesia Pulmonary TB 108 115 rs2273061 JAG1 1.8 [1.18–2.72] (73)
– – – – rs4461087 DYNLRB2 1.62 [1.1–2.37] –
– – – – rs1051787 EBF1 0.57 [0.38–0.88] –
– – – – rs10497744 TMEFF2 0.55 [0.38–0.82] –
– – – – rs1020941 TMEFF2 0.57 [0.38–0.83] –
rs188872 CCL17 0.51 [0.33–0.78] –
– – – – rs10245298 HAUS6 2.37 [1.09–5.16] –
– – – – rs6985962 PENK 2.01 [1.12–3.61] –
– – – – rs1418267 ERP44 3.19 [1.71–5.99] –
Ghana TB 2127 5636 rs2057178 WT1 (intergenic) 0.77 [0.71–0.84] (74)
Gambia – 1207 1349 – – 0.80 [0.70–0.91] –
Russia – 1025 983 – – 0.91 [0.82–0.99] –
Indonesia – 4441 5874 – – 0.84 [0.68–1.03] –
South Africa Pulmonary TB 642 91 rs2057178 WT1 (intergenic) 0.62 [0.50–0.75] (75)
– – – – rs11031728 WT1 (intergenic) 0.61(0.50–0.75) –
Russia Pulmonary TB 5530 5607 rs4733781 ASAP1 0.84 [0.79–0.89] (76)
– – – – rs10956514 ASAP1 0.85 [0.80–0.90] –
– – – – rs1017281 ASAP1 0.85 [0.81–0.90] –
– – – – rs1469288 ASAP1 0.84 [0.79–0.89] –
– – – – rs17285138 ASAP1 0.85 [0.80–0.90] –
– – – – rs2033059 ASAP1 0.83 [0.79–0.88] –
– – – – rs12680942 ASAP1 0.84 [0.79–0.89] –
Morocco Pulmonary TB 556 650 rs358793 Intergenic 0.68 [0.57–0.82] (77)
– – – – rs17590261 Intergenic 6.24 [2.38–16.33] –
– – – – rs6786408 FOXP1 1.47 [1.23–1.79] –
– – – – rs916943 AGMO 1.86 [1.33–2.6] –
Uganda HIV positive TB resistance 267 314 rs4921437 IL12B 0.37 [0.27–0.53] (78)
Tanzania – – – – – – –
Iceland TST positivity 8162 277643 rs557011 Between HLA-DQA1 and HLA-DRB1 1.25 [1.17–1.33] (79)
– – – – rs9271378 Between HLA-DQA1 and HLA-DRB1 0.78 [0.73–0.84] –
– – – – rs9272785 HLA-DQA1 1.14 [1.09–1.19] –
Uganda TST reactivity 224 225 rs877356 IL9 0.27 [0.17–0.42] (80)
Tanzania – – – – – – –
23 and Me
(European
ancestry)
Positive TST 4426 84290 rs2894257 HLA 1.36 [1.33–1.39] (81)
China (Han
Chinese)
Pulmonary and
extrapulmonary TB
4310 6386 rs4240897 MFN2 0.79 [0.75–0.83] (82)
– – – – rs41553512 HLA class II 2.14 [1.78–2.57] –
– – – – rs2269497 RGS12 1.51 [1.35–1.68] –
Thailand Non-Beijing lineage-infected
old age onset
182 489 rs1418425 CD53 1.74 [1.43–2.12] (83)
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(81). The HLA rs2894257 variant on chromosome 6p21.32 was
significantly associated with the presence of a TST induration
(p = 8.16 × 10−36, OR 1.36, 95% CI 1.33–1.39) and then
after further fine mapping of the locus multiple independent
associations between a history of a positive TST and HLA
were detected (Table 1) (81). The HLA class II region could
contribute to infection resistance by reduced presentation of M.
tuberculosis antigens to T cells (79). In Uganda, a genome-wide
linkage analysis (GWLA) reported suggestive, but not significant,
linkage of persistent TST negativity (defined as a TST < 10
or 5mm according to age and HIV status) with chromosomal
regions 2q21-2q24 and 5p13-5q22 (84). The chromosome 2q
region was subsequently investigated using an association scan
in two independent cohorts from Uganda and associations were
found with variants in the Zinc finger E-box-binding homeobox
2 (ZEB2) and Glycosyltransferase Like Domain Containing 1
(GTDC1) genes (85). These variants may regulate the histone
deacetylase pathway, which has been implicated in infection
resistance by transcriptomic investigations (discussed below)
(86). Two loci were identified by GWLA in an HIV negative
population from South Africa (87). TST1 was identified on
chromosome 11p14 by focusing on the phenotype of TST >
0mm vs. TST= 0mm, and captures innate resistance to infection
with M. tuberculosis. TST2 was mapped to region 5p15 and
influences the intensity of TST reactivity - captured as TST
induration in mm. Hence, TST2 reflects intensity of T-cell
mediated anti-mycobacterial immune responses. Themapping of
TST1 has been confirmed in an independent sample of different
ethnic origins in France, and it was also shown that TST1 cannot
be distinguished by linkage from TNF1, a locus controlling TNF
production in response to BCG/IFN-gamma (88, 89).
Compared to the study ofM. tuberculosis infection resistance,
a larger number of investigations have been published addressing
the genetic factors that protect against or predispose to
developing clinical TB. Indeed, 11 TB GWAS have been done
using clinical TB as phenotype [Table 1, reviewed by (20, 21)].
Highlights included the identification of the 11p13 locus first
identified in West Africa and replicated in Russia, Indonesia
and South Africa (74, 75), a large Icelandic GWAS which
identified HLA class II variants which was weakly replicated in
Russia and Croatia (79) and a recent GWAS of TB resistance
in HIV positive individuals from hyperendemic TB regions
in Uganda and Tanzania (78). The latter study found an
association with a locus at chromosome region 5q33.3. The
associated variant is embedded in an H3K27A histone mark,
but is also in a genomic region that includes IL12B, a gene
known to underlie Mendelian susceptibility to mycobacterial
disease (78).
Since the publication of previous reviews of clinical TB GWAS
(20, 21), two additional studies have been completed using this
study design. A three-stage replication approach was used in the
Han Chinese and generated genotyping data (691 388 SNPs) for
972 TB cases and 1537 controls in the first stage (82). In the
second stage, the top 45 loci were analyzed in 2278 TB cases
and 2752 controls and the nine most significant variants were
genotyped in 1060 TB cases and 2752 controls. Variants in three
loci, namely MFN2 (rs4240897, p = 1.41 × 10−11, OR 0.79, 95%
CI 0.75–0.83), HLA class II (rs41553512, p = 7.93 × 10−11, OR
2.14, 95% CI 1.78–2.57), and RGS12 (rs2269497, p = 3.37 ×
10−8, OR 1.51, 95% CI 1.35–1.68) were significantly associated
with TB in a meta-analysis of the three stages (4310 cases vs.
6386 controls). These are all excellent TB candidate genes and
gene expression data supported the functional significance of
two of the identified variants. The rs4240897 variant regulates
MFN2 expression suggesting that this variant could affect platelet
count and macrophage differentiation. In addition, expression
of this gene was increased in TB cases compared to controls
(82). Another gene in close proximity to rs4240897 is TNFRSF8
and expression of this immune gene was lower in TB cases
than controls. Signaling of the TNFSF8/TNFRSF8 pathway
enhanced interferon gamma production in response to M. bovis
BCG stimulation (82). A GWAS done in Thailand relied on
M. tuberculosis pathogen lineage information and identified a
chromosome 1p13 association between 489 healthy controls
and 182 cases with non-Beijing lineage-infected old age onset
(rs1418425, p = 2.54 × 10−8, OR 1.74, 95% CI 1.43–2.12) (83).
The variant is located in the vicinity of the CD53 gene and
expression of this leukocyte surface glycoprotein was correlated
with active TB (83). In addition, the rs1418425 variant is a known
cis-expression quantitative trait locus in M. tuberculosis infected
dendritic cells (83).
Clearly there is very little overlap with respect to the loci
detected between the individual GWAS, but it seems that
replication is more likely when populations with similar genetic
backgrounds are compared. This was seen for the WT1 locus
in West and South Africa and it is possible that the same HLA
class II factors are being tagged in Icelandic and other European
populations, but this is not known at this point (74, 75, 79,
81). When GWAS data from Han Chinese and Gambians were
combined in a meta-analysis, no significant associations were
detected (82). Deciphering the complete genetic architecture of
a complex trait requires more than a single ancestry, as was the
case for skin pigmentation genes and other phenotypes (90, 91).
For this reason, population genetics also has to be considered
in investigations of TB resistance (92). Excess European, South
Asian and East Asian ancestry protects admixed South African
individuals against active TB, whereas excess African ancestry
increased the risk for developing disease. These disparities in
disease incidence were harnessed in a TB admixture mapping
study (75, 93). The contribution of ethnicity to TB resistance may
be due to selection after centuries of exposure to M. tuberculosis
(as discussed in the section “Early epidemiological evidence
of natural TB resistance”). This is supported by findings that
individuals with diverse genetic backgrounds have different rates
of TB infection and disease progression (not affected by socio
economic circumstances) and the intensity of immune responses
differ (35, 52–54, 59).
FUNCTIONAL GENETICS
The mechanisms through which genetic variation contributes to
TB resistance require functional follow-up to support statistical
findings of epidemiological studies. Investigations of epigenetics,
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microRNAs, and other products of transcription can provide
functions to these genetic variants, but can also identify novel
genes and pathways involved with TB resistance (94).
Transcriptomics
Transcriptional profiles generated from blood cells have
contributed to the elucidation of pathways involved in resistance
to infection. Genome-wide transcriptional profiles from infected
monocytes isolated from TST positive and persistently negative
household contacts from Uganda who did not develop TB at
least two years after follow-up were generated using microarrays
(86). Pathways controlled by histone deacetylase were associated
with resistance toM. tuberculosis infection and indicated that this
function is vital in the early innate immune response to infection
(86). Although this anti-inflammatory mechanism holds promise
as a therapy, the in vitro findings may not extend to effects in
vivo. The use of histone deacetylase inhibitors did not increase
survival in a sepsis model (95) and histone deacetylase-related
genes were also expressed in TST positive individuals (86). In
a non-human primate model, a signature of 34 pre-infection
transcripts could differentiate between animals that would
progress to active disease or develop LTBI (96). Twelve of the
upregulated transcripts were associated with interferon, cell cycle
and inflammation processes. When the outcome was stratified
based on 18F-fluorodeoxyglucose (FDG) positron emission
tomography coupled with computed tomography (PET CT), 30
pre-infection transcripts were differentially expressed between
animals with low and high FDG avidity. The differentially
expressed genes did not correspond to the clinical status or
lung avidity groups, but function in the same pathways related
to inflammation and interferon (96). The inherent genetic
ability of the host to upregulate these pathways may correspond
to poor infection outcomes (96). Importantly, both studies
underline that a balanced inflammatory response, regulated
by the host genome, is critical to determine the outcome of
infection (86, 96).
Although genome-wide transcriptomic studies of TB infection
resistance are in their infancy, many studies have identified
blood gene expression signatures for the classification of the TB
pathogenesis stages (including the diagnosis of active TB) and
monitoring of treatment efficacy (97–112). The value of these
studies lies in their predictive accuracy, since TST and IGRAs
cannot fulfill this function (21). However, transcriptomics cannot
detect those genetically determined for disease progression
before the onset of the process (21). Several predictive signatures
of TB risk have been developed from whole blood RNA
sequencing. Recently a four-transcript signature, labeled RISK4,
could predict disease progression up to 2 years before TB
symptoms presented in Africa cohorts from South Africa, The
Gambia and Ethiopia (113). This signature consists of two
upregulated (growth arrest–specific 6 and septin 4) and two
downregulated (cluster of differentiation 1C and B lymphocyte
kinase) genes. A 16 gene predictive signature of TB risk was
developed from whole blood RNA sequencing of adolescents and
could not only identify individuals at risk of developing active
TB after LTBI, but could also distinguish active disease from
LTBI and other disease forms in two African populations and
three validation samples (114). The sixteen genes were Ankyrin
repeat domain 22, Apolipoprotein L1, basic leucine zipper ATF-
like transcription factor 2, ETS Variant 7, Fc Fragment Of
IgG Receptor Ia, Fc Fragment Of IgG Receptor Ib, Guanylate
Binding Protein 1,2,4, and 5, Scavenger Receptor Class FMember
1, septin 4, Serpin Family G Member 1, Signal Transducer
And Activator Of Transcription 1, Transporter 1, ATP Binding
Cassette Subfamily B Member and TRAF-Type Zinc Finger
Domain Containing 1. In HIV positive drug users with and
without TB, expression of the IL-13 and autoimmune regulator
genes were predictive of developing disease even 8 months before
the actual diagnosis (115), but this signature was not validated
in the RNA sequencing study of HIV negative adolescents (114).
To identify correlates of TB resistance using the LTBI phenotype
as a proxy, network analysis was applied to a number of TB
transcriptomic datasets. Here the focus was specifically on gene
expression profiles of macrophages, as these cells can mount an
antimicrobial response (116). IL-32 was identified as a functional
marker of resistance to active TB andmediated interferon gamma
vitamin D dependent antimicrobial immunity (16, 116). An in
vitro investigation of monocytes (isolated from LTBI and active
TB individuals) after M. tuberculosis infection indicated that IL-
26 downregulation was beneficial to anti-mycobacterial activity,
making it a plausible susceptibility candidate gene (94). A meta-
analysis of 16 published studies identified a set of 380 genes that
were differentially expressed in active TB in most investigations
with interferon gamma as themost significant potential upstream
regulated molecule (117).
Epigenetics
The contribution of epigenetic mechanisms to the regulation
of inflammatory immune responses in TB is an emerging field
and evaluations of the genetic regulation of transcriptomic
responses can assist in revealing the biology of TB host resistance
(118). Epigenetic regulation incorporates all chromosomal
modifications that alter gene expression without changing the
underlying coding DNA nucleotide sequence, such as DNA
methylation and histone acetylation. Methylation events in
monocytes and granulocytes could discriminate between TB
cases and healthy LTBI controls (119).
Histone modifications have been linked to mTOR dependent
regulation of glucose and glutamine metabolism in BCG-trained
monocytes and macrophages, with histone H3 trimethylation
of lysine 4 (H3K4me3) found to be significantly increased at
the promotors of mTOR, HK2 and PFKP, while trimethylation
of lysine 9 (H3Kme3) was significantly decreased (120).
Histone H3 hypoacetylation, specifically at lysine 14 (H3K14ac)
was associated with active pulmonary TB (121) as well as
being essential for the activation of several pro-inflammatory
cytokines (122, 123). Interestingly, the macrophage response
to different immune challenges can result in the generation
of histone marks associated with de novo enhancer elements
(124, 125). These marks have been hypothesized to cause
the epigenetic reprogramming of the macrophages leading
to a stronger transcriptional response to a second stimulus
(124). In addition to histone modifications, recent data
suggests that DNA methylation also plays a significant role
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in in the reprogramming of innate immune cells and the
regulation of transcriptional programs following M. tuberculosis
infection (126).
Epigenetic modification of histone acetylation in monocyte-
derived macrophages plays a significant regulatory role in M.
tuberculosis-dependent gene expression and in the secretion of
matrix metalloproteinase enzymes driving immunopathology.
Modification of histone acetylases has implications for TB
resistance too, based on the findings of Seshadri et al. discussed
above (86). Variants in the regulatory regions of over 700 genes
that were up- or downregulated after M. tuberculosis infection
of monocyte-derived dendritic cells significantly influenced gene
expression regardless of the stimulation status of cells. (127).
These variants are expression quantitative trait loci (eQTL)
and a subset of these (response-eQTL) were dependent on
M. tuberculosis stimulation, indicating that epigenetic effects
contribute to TB pathogenesis (126). Manipulating these
regulatory mechanisms may have potential as host-directed
therapy (128).
MicroRNAs
MicroRNAs (miRNAs) play a crucial role in TB pathogenesis
(129). MiRNAs are short, non-coding RNA molecules that
regulate mRNA translation and degradation and affect the
function of many immune cell types (129). Used as markers,
miRNAs can distinguish between active disease, LTBI or
other microbial infections (130–137), and also influence TB
susceptibility, specifically miR-155 andmiR-223 (138–141). MiR-
223 directly targeted chemoattractants such as CXCL2, CCL3,
and IL-6 to control neutrophil driven inflammation (138, 139).
When miR-223 was deleted in a TB resistant mouse model
these animals became extremely susceptible to TB, but the
phenotype could be partly restored through the neutralization
of the abovementioned chemoattractants (138). miR-155 was
highly expressed after mycobacterial infection both in vivo and
in vitro (139). The induced expression of miR-155 enhanced
the autophagic response in macrophages thereby stimulating
mycobacterial phagosome maturation and reducing the survival
rate of intracellular mycobacteria. In contrast, when miR-155
was inhibited, there was increased mycobacterial survival. The
mechanism of action of miR-155 is through the targeting
of Ras homolog enrich in brain (Rheb), a known negative
regulator of autophagy. When miR-155 was bound to the 3’-
untranslated region of Rheb, both autophagy and intracellular
killing of mycobacteria were increased (139). In addition to
expression analysis, genetic variants in miR-499 and miR-146a
were associated with pulmonary TB susceptibility in a case-
control association study (142).
Transgenic Animals
Although the animal models (discussed in the section “Early
epidemiological evidence of natural TB resistance”) were initially
used to study the natural occurrence of TB resistance, advances
in molecular genetic techniques have facilitated the creation of
resistant species. Transgenic cattle with a knock-in SP110 nuclear
body protein (SP110) gene were created using transcription
activator-like effector nuclease (TALEN)-mediated genome
modification (143). The mouse homolog of this gene, Ipr1, was
previously shown to mediate innate immunity in sst1 congenic
mice and SP110 variants were associated in some settings with
human pulmonary TB (144, 145), but not others (146–149). In
the transgenic cattle apoptosis instead of necrosis was activated
after infection (143). In vivo and in vitro experiments indicated
that these animals could control growth and proliferation of M.
bovis. Significantly, transmission experiments using tuberculous
cattle indicated that the transgenic animals were resistant to low
doseM. bovis infection (143).
CONTROVERSIES, CURRENT RESEARCH
GAPS, AND FUTURE DEVELOPMENTS
The four complementary theories of infectious disease propose
that inter-individual variability in presentation depends on four
factors, namely microbiological, ecological, immunological, and
genetic (150). These elements not only intersect but are all
required to dissect a complex infection phenotype such as TB
resistance (150). To delineate the contribution of genetic factors
will require innovative new approaches to combine available
data sets to understand the resistance phenomenon, in particular
in HIV-infected persons. Integrated clinical and laboratory
defined phenotypes, whole genome sequencing, epigenetic
and transcriptomic studies will be required to address this
challenge.
The co-evolution of M. tuberculosis and humans has shaped
host-pathogen interactions for thousands of years and has likely
contributed to the diverse range of responses after infection
including the phenotype of the TB resister (50, 61, 151). Host-
pathogen interaction investigations are however complicated by
the genetic heterogeneity of the bacterium (50). One approach
is to use M. tuberculosis pathogen lineage information as was
done for a TB GWAS in Thailand (Table 1) and several candidate
gene association studies (83, 152–155). Despite the challenges,
developments in this area could in future be used to design
targeted vaccines and therapies directed to specific populations
or individuals (50).
Several TB GWAS have interrogated resistance to disease,
but most of these have been underpowered due to the extreme
phenotypic heterogeneity. Meta-analyses can provide a solution
to this problem and could provide insight into population-
specific associations by harnessing linkage disequilibrium to
fine map associations. The International TB Host Genetics
Consortium has been established to collate TB GWAS data from
individuals with pulmonary TB and healthy controls to do a
large-scale meta-analysis (156). This large-scale approach will
not be feasible to investigate persistently TST/IGRA negative
individuals, since phenotyping is a costly process and requires
several repeat assays to exclude those who revert and convert.
Fortunately, since the TB resister phenotype is at the end
of the TB susceptibility spectrum, it is possible that variants
contributing to this extreme phenotype can be detected in limited
sample sizes, as has been seen in investigations of HIV-infected
participants who do not become infected or progress to active TB
despite living in a TB endemic region (78, 86).
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Finally, genome sequencing technologies, which are already
used to diagnose individuals with Mendelian susceptibility
to mycobacterial diseases, will deliver resistance variants not
captured bymicroarray genotyping and imputing. Once genomes
from TB resisters are available for data mining and analysis in
system biology approaches—which will include transcriptomics,
epigenomics, microbiomics, and other omics, we may be able
to achieve prediction of individuals genetically determined as
resistant.
CONCLUSION
The involvement of a human genetic component in susceptibility
to infection with M. tuberculosis and progression to active
disease is incontestable. Findings from clinical genetics, genetic
epidemiology, population and functional genetics have all
contributed to identify TB susceptibility genes. More intriguing
is the other side of the phenotypic coin—that of resistance to
either initial infection or, after infection, resistance to progression
to disease. Although the phenomenon is now recognized,
the exact genetic variants and mechanisms that contribute
still require elucidation. The most successful approaches in
resistance/susceptibility investigation have focused on specific
infection and disease phenotypes and the resister phenotype may
hold the key to the discovery of actionable genetic variants in TB
infection and disease.
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